PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer

✍ Scribed by Schwartzberg, L. S.; Rivera, F.; Karthaus, M.; Fasola, G.; Canon, J.-L.; Hecht, J. R.; Yu, H.; Oliner, K. S.; Go, W. Y.

• Book ID: 121690712
• Publisher: American Society of Clinical Oncology
• Year: 2014
• Tongue: English
• Weight: 520 KB
• Volume: 32
• Category: Article
• ISSN: 0732-183X
• DOI: 10.1200/jco.2013.53.2473